All In Biotech

Drug Trial Radar · NCT06834932

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia

A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants With Dyslipidaemia (AZURE-CHINA)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

432

Actual

Start

Dec 6, 2024

Primary completion

Feb 22, 2027

Study completion Feb 22, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind, placebo-controlled, multi-centre, sequential Phase II and Phase III study that will evaluate the efficacy, safety, and PK of AZD0780 administered orally for up to 52 weeks in participants with elevated LDL-C. The study consist of 2 separate parts (Part A and Part B) approximately 60 participants will be randomised in Part A. There will be 2 cohorts in Part B (approximately 220 participants in Cohort 1 and 100 participants in Cohort 2).

Conditions

  • Dyslipidaemia

Interventions

  • PlaceboDrug

    Administered orally as tablets

  • Rosuvastatin Dose 1Drug

    Administered orally as tablets

  • Rosuvastatin dose 2Drug

    Administered orally as tablets

  • AZD0780Drug

    Administered orally as tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AZD0780 Concentrations in plasma (PART A)Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
  2. AZD0780 PK Parameter: AUC0-t (PART A, intensive PK subgroup).Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
  3. AZD0780 PK parameter: Cmax (PART A, intensive PK subgroup)Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
  4. AZD0780 PK parameter: AUCtau (PART A, intensive PK sub group)Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
  5. Relative change in LDL-C from baseline to 12 weeks (PART B)Time frame: From baseline to 12 weeks (PART B)

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Baotou, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Bengbu, China

  • Research Site

    Changchun, China

  • Research Site

    Changchun, China

  • Research Site

    Changde, China

  • Research Site

    Changsha, China

  • Research Site

    Changzhou, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Daqing, China

  • Research Site

    Deyang, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Hengyang, China

  • Research Site

    Heze, China

  • Research Site

    Linhai, China

  • Research Site

    Luoyang, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanchong, China

  • Research Site

    Nanjing, China

  • Research Site

    Pingxiang, China

  • Research Site

    Qiqihar, China

  • Research Site

    Sanya, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Shenyang, China

  • Research Site

    Siping, China

  • Research Site

    Taiyuan, China

  • Research Site

    Tianjin, China

  • Research Site

    Wuhan, China

  • Research Site

    Wuhan, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

  • Research Site

    Xianyang, China

  • Research Site

    Yinchuan, China

  • Research Site

    Zigong, China

  • Research Site

    Hong Kong, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.